Sunshine Biopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sunshine Biopharma, Inc. (SBFM) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-5.13-4.51-26.74-12.44-2.78
Depreciation & Amortization0.220.150.030.010.01
Stock Based Compensation0.010.000.000.920.05
Change in Working Capital-7.63-4.423.15-0.11-0.04
Change in Accounts Receivable-2.34-0.59-0.52-0.010.00
Change in Inventory-6.01-2.370.04-0.08-0.01
Change in Accounts Payable3.98-1.363.36-0.02-0.04
Change in Other Working Capital-2.46-0.020.030.980.00
Other Operating Activities-2.240.00-0.010.982.11
Net Cash from Operating Activities-12.53-8.78-5.25-1.83-0.66
Investing Activities
Capital Expenditures-1.66-0.08-0.190.000.00
Acquisitions0.000.00-14.350.000.00
Sales/Maturities of Investments-0.32-0.71-0.110.000.00
Other Investing Activities-0.340.130.030.000.00
Net Cash from Investing Activities-2.32-0.66-14.620.000.00
Financing Activities
Debt Repayment0.35-0.13-1.93-0.48-0.11
Common Stock Issued12.084.0943.560.000.00
Common Stock Repurchased-3.14-0.54-0.100.000.00
Other Financing Activities3.560.00-2.060.060.04
Net Cash from Financing Activities9.293.4339.472.901.61
Summary
Effect of Forex Changes on Cash-1.040.470.18-0.020.00
Net Change in Cash-6.61-5.5319.781.080.95
Cash at Beginning of Period16.2921.832.050.990.00
Cash at End of Period9.6916.2921.832.050.00
Free Cash Flow-14.19-8.86-5.44-1.83-0.66
Supplemental Disclosures
Interest Paid0.010.000.050.040.02
Income Taxes Paid0.580.000.000.000.00